{
"@context": "/terms/",
"@id": "/tabular-files/IGVFFI4854DWEG/",
"@type": [
"TabularFile",
"File",
"Item"
],
"accession": "IGVFFI4854DWEG",
"aliases": [
"jesse-engreitz:IL2RA_promoter_tiling_Jurkat-Stimulation_Variant-EFFECTS_File_Standardized"
],
"assay_titles": [
"Variant-EFFECTS"
],
"assembly": "GRCh38",
"audit": {},
"award": {
"@id": "/awards/HG011972/",
"component": "functional characterization"
},
"barcode_map_for": [],
"checkfiles_version": "v20",
"content_md5sum": "529a6f2e2ada8fff63fe8cb468045df1",
"content_type": "variant effects",
"controlled_access": false,
"creation_timestamp": "2025-03-29T00:12:51.324645+00:00",
"derived_from": [
"/tabular-files/IGVFFI9903UNGI/"
],
"derived_manually": true,
"description": "Manually standardized output of Variant-EFFECTS pipeline, formatted for GRCh38 with SPDI variant IDs",
"file_format": "tsv",
"file_format_specifications": [
{
"@id": "/documents/9d0ad6fb-777c-4cb6-a1c4-8ff7a41b17a1/",
"description": "This file type describes results from genome editing experiments that measure the effect of a variant on an endogenous gene in the genome."
}
],
"file_set": {
"@id": "/analysis-sets/IGVFDS1824XDMU/",
"@type": [
"AnalysisSet",
"FileSet",
"Item"
],
"accession": "IGVFDS1824XDMU",
"data_use_limitation_summaries": [
"no certificate"
],
"file_set_type": "principal analysis",
"samples": [
{
"@id": "/in-vitro-systems/IGVFSM6795SCHR/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM6795SCHR",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM8079DJVX/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM8079DJVX",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM5388SXBN/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM5388SXBN",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9103RFFD/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9103RFFD",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9448WLVQ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9448WLVQ",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM8345LMXC/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM8345LMXC",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM1871BLFB/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM1871BLFB",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM5709XAIS/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM5709XAIS",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4784GKZI/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4784GKZI",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7816WZNZ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7816WZNZ",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM2330LAXQ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM2330LAXQ",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9894RFCK/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9894RFCK",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7352WPEI/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7352WPEI",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM3690RUXJ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM3690RUXJ",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9297KXBW/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9297KXBW",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM2690PEZO/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM2690PEZO",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4553KVCE/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4553KVCE",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 76-100% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7206IJBO/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7206IJBO",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM1469NQHM/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM1469NQHM",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4954YHLR/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4954YHLR",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM7312DZBH/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM7312DZBH",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM4883HGPU/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM4883HGPU",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM9146UAUA/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM9146UAUA",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 26-50% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM1409FVBR/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM1409FVBR",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 51-75% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
},
{
"@id": "/in-vitro-systems/IGVFSM8750WCGQ/",
"@type": [
"InVitroSystem",
"Biosample",
"Sample",
"Item"
],
"accession": "IGVFSM8750WCGQ",
"classifications": [
"cell line"
],
"modifications": [
{
"@id": "/crispr-modifications/fc6bc0b3-a064-47d0-b95d-a9af14bb1624/",
"modality": "prime editing",
"status": "released",
"summary": "CRISPR prime editing Sp-nCas9-M-MLV RT (PE2)"
}
],
"sample_terms": [
{
"@id": "/sample-terms/EFO_0002796/",
"status": "released",
"term_name": "Jurkat"
}
],
"status": "preview",
"summary": "Homo sapiens (male) Jurkat cell line (sorting details: FACS bin for 0-25% expression of IL2RA) treated with 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours, 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours, modified with CRISPR prime editing Sp-nCas9-M-MLV RT (PE2), transduced (lentivirus) with a guide library",
"taxa": "Homo sapiens",
"treatments": [
{
"@id": "/treatments/4b5f0d13-ec20-4b91-85f5-a009cd91451f/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 100 ng/mL phorbol 13-acetate 12-myristate for 24 hours",
"treatment_term_name": "phorbol 13-acetate 12-myristate"
},
{
"@id": "/treatments/cf87f410-54ee-48ef-b654-8443c4fee032/",
"purpose": "stimulation",
"status": "in progress",
"summary": "Treatment of 5 μg/mL T-cell surface glycoprotein CD3 gamma chain for 24 hours",
"treatment_term_name": "T-cell surface glycoprotein CD3 gamma chain"
}
]
}
],
"status": "preview",
"summary": "CRISPR prime editing Variant-EFFECTS targeting IL2RA integrating a guide (sgRNA) library targeting sequence variants in a genomic locus"
},
"file_size": 5771,
"gene_list_for": [],
"href": "/tabular-files/IGVFFI4854DWEG/@@download/IGVFFI4854DWEG.tsv.gz",
"input_file_for": [],
"integrated_in": [],
"lab": {
"@id": "/labs/jesse-engreitz/",
"title": "Jesse Engreitz, Stanford"
},
"loci_list_for": [],
"md5sum": "b765337b37be90768d15a783f67453fb",
"primer_design_for": [],
"quality_metrics": [],
"s3_uri": "s3://igvf-files/2025/03/29/ab710abf-4b51-453b-897a-cfaf5ec08171/IGVFFI4854DWEG.tsv.gz",
"schema_version": "15",
"status": "preview",
"submitted_by": {
"@id": "/users/f9e7cd82-a407-4a20-89ee-f4dc668b0cbe/",
"title": "Michael Montgomery"
},
"submitted_file_name": "IL2RA_promoter_tiling_Jurkat-Stimulation_VariantEffectsFile.tsv.gz",
"submitter_comment": "The original outputs from the Variant-EFFECTS pipeline report VariantIDs in the hg19 format. To obtain the standardized variant information provided in this file, hg19 coordinates were lifted to hg38 using the UCSC LiftOver tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver). Then, canonical, validated SPDIs were generated and validated using the igvf_spdi_demo tool (https://github.com/mikelove/igvf_spdi_demo).",
"summary": "GRCh38 variant effects",
"upload_status": "validated",
"uuid": "ab710abf-4b51-453b-897a-cfaf5ec08171"
}